期刊文献+

卵巢Sertoli-Ledig细胞瘤临床病理分析

卵巢Sertoli-Ledig细胞瘤临床病理分析
下载PDF
导出
摘要 目的探讨卵巢Sertoli-Ledig细胞瘤(SLCT)的临床特征和病理诊断,以利于SLCT的准确诊断和生物学行为评价及指导治疗。方法分析了SLCT2例的临床特征、病理诊断和治疗方法及预后,并结合相关文献复习。结果 2例患者年龄分别为27、39岁,发生部位右侧卵巢1例,左侧卵巢1例。其中1例行患侧附件切除术,术后化疗。另1例行全子宫加患侧附件切除术。经短期随访均健在。结论临床上该瘤总的预后较好,手术为该肿瘤治疗的主要方式,年轻患者或有生育要求者行保守性手术,高龄且中、低分化型患者行全子宫及双侧附件切除,术后辅以化疗。 Objective To explore the clinical feature and pathological diagnosis of ovarian Sertoli-Ledig cell tumor.Methods two cases of SLCTs were analyzed by clinical data,pathomorphology ,therapeutic method and prognosis.And in conjunction with the relevant literature review Results The two patients were in age of 27 and 39 years,the tumors were located in the right ovary and left ovary respectively. Case 1 line of primary attachments resection, and postoperative adjuvant chemotherapy.case 2 did the whole uterine and lateral accessories resection. Both the short-term follow-up without recurrence.Conclusion Clinically this tumor generally prognosis is good, the operation is the main way of tumor treatment Young patients or have fertility demander line conseratie surgery, older and medium, low differentiated type patients do the whole uterine and bilateral accessories resection, postoperative complementary with chemotherapy.
作者 王晓红
出处 《当代医学》 2011年第35期113-114,共2页 Contemporary Medicine
关键词 卵巢Sertoli-Ledig细胞瘤 临床特征 病理诊断 治疗 Ovarian Sertoli-Ledig cell tumor Clinical feature Pathological diagnosis Treatment
  • 相关文献

参考文献11

  • 1Tavassoli FA,Devilee P.World Health Organization calssification of tumours.Pathology and genetics tumours of the breast and female genital organs[J].Lyon:IARC,2003,292:159.
  • 2Young R H,Scully R E.0varian Sertoli-Leydig cell tumors.A clinicopathological analysis of 207 cases[J].Am J Surg Pathol,1985,9(8):543-569.
  • 3Yao D X,Soslow R A,Hedvat C V,et al.Melan-A(A103) and inhibin expression in ovarian neoplasms[J].Appl Immunohistochem Mol Morphol,2003,11(3):244-249.
  • 4任永昌,甄宏伟,朱素玲,李守村,叶涛,董正,肖成涛.α-抑制素CD99联合应用在卵巢性索间质肿瘤表达意义的研究[J].河北医学,2005,11(1):12-15. 被引量:10
  • 5Baranova A,Gowder S,Naouar S,et al.Expression profile of ovarian tumors:distinct signature of Sertoli-Leydig cell tumor[J].Int J Gynecol Cancer,2006,16(6):1963-1972.
  • 6Verdorfer I,Horst D,Hollrigl A,et al.Sertoli-Leydig cell tumours of the ovary and testis:a CGH ang FISH study[J].Virchows Arch,2007,450(3):267-271.
  • 7Truss L,Dobin SM,Rao A,et al.Overexpression of the BCL2 Gene in a Setoli-Ledig cell tumor of the ovary:a pathologic and cytogenetic study[J].Cancer Genet Cytogenet,2004,148(2):118-122.
  • 8Zhang M,Cheung MK,Shin JY,et al.Prognostic factors responsible for survival in sex cord stromal tumors of the ovary:a n analysis of 376 women.Gynecol Oncol[J],2007,104(2):396-400.
  • 9Part J,Young RH,Scully RE.Ovarian Sertoli-Leydig cell tumors with heterologous elements.II.Cartilage and skeletal muscle:a clinicopathologic analysis of twelve cases[J].Cancer,1982,50(11):2465-2475.
  • 10Grove A,Vestergaard V.Ovarian Sertoli-Leydig cell tumor of intermediate grade with heterologous elemnts of rhabdomyosarcoma.Acase report and a review of the literature[J].Ann Diagn Pathol,2006,10(5):288-293.

二级参考文献6

  • 1陈中年 杜心谷 刘伯宁.性索-间质性肿瘤妇产科病理学[M].上海医科大学出版社,1996.218-226.
  • 2Gordon MD,Corless C,Renshaw AA,et al.CD99,keratain,and vimentin staining of sex cord-stromal tumors,normal ovary,and testis[J].Mod Pathol,1998,11:769-773.
  • 3Choi YL,Kim HS,Ahn G.Immunoexpression of inhibin alpha subunit,inhibin/activin betaA subunit and CD99 in ovarian tumors[J].Arch Pathol Lab Med,2000,124:563-569.
  • 4McCluggage WG.Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms[J]. Clin Pathol,2000,53:327-334.
  • 5冯静,崔恒,魏丽惠.抑制素在卵巢恶性肿瘤中的应用[J].中华妇产科杂志,2000,35(10):636-637. 被引量:3
  • 6郭东辉,范敬东,师宜荃,王萍.CD99在卵巢性索-间质肿瘤中的表达[J].中华病理学杂志,2002,31(3):257-258. 被引量:9

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部